GlassScriptPhysician profile
Donna S Mccormick
NPI 1255494902
$9,728.50
in general payments reported to CMS, 2019-2025
39 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,787 · 2022: $4,523 · 2023: $1,374 · 2024: $972 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,339 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,338.67 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,761.74 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $650.85 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $530.02 | 2021-2025 | Caplyta |
| Novo Nordisk INC | $435.58 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Pfizer INC. | $397.08 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $372.29 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $212.91 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $203.01 | 2023-2024 | Veozah |
| Vanda Pharmaceuticals INC. | $198.85 | 2022-2024 | Fanapt, Hetlioz |
| Biohaven Pharmaceuticals, INC. | $190.14 | 2021 | |
| Intra-Sana Laboratories | $178.64 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $177.00 | 2021-2023 | Trintellix |
| Merz North America, INC. | $148.54 | 2024 | |
| Janssen Pharmaceuticals, INC | $147.53 | 2022-2023 | Spravato |
| Jazz Pharmaceuticals INC. | $121.01 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.